Compound 115
Identifiers
- Canonical SMILES:
CN(C)CCC[C@](O)(c1ccccc1)c1ccc(OCCc2cccc(c2)-c2ccc(cc2)C(O)=O)cc1
- IUPAC name:
4-[3-[2-[4-[4-(dimethylamino)-1-hydroxy-1-phenylbutyl]phenoxy]ethyl]phenyl]benzoic acid
- InChi:
InChI=1S/C33H35NO4/c1-34(2)22-7-21-33(37,29-10-4-3-5-11-29)30-16-18-31(19-17-30)38-23-20-25-8-6-9-28(24-25)26-12-14-27(15-13-26)32(35)36/h3-6,8-19,24,37H,7,20-23H2,1-2H3,(H,35,36)/t33-/m0/s1
- InChiKey:
APSPXYQCUPNVKV-XIFFEERXSA-N
External links
52948158 |
26362657 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 5.10 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 509.26 g/mol | |||
HBA | 5 | |||
HBD | 2 | |||
HBA + HBD | 7 | |||
AlogP | 3.80 | |||
TPSA | 70.00 | |||
RB | 12 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.6283 | Ansofaxine | DB15052 | |
0.5810 | Adapalene | DB00210 | |
0.5785 | Darifenacin | DB00496 | |
0.5635 | {4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone | DB07237 | |
0.5588 | Fexofenadine | DB00950 | |
0.5517 | Fesoterodine | DB06702 | |
0.5514 | Dyclonine | DB00645 | |
0.5385 | Lifibrol | DB12448 | |
0.5328 | Adomeglivant | DB11704 | |
0.5238 | Ormeloxifene | DB13310 | |
0.5224 | 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid | DB04405 | |
0.5204 | Terfenadine | DB00342 | |
0.5155 | Diphenidol | DB01231 | |
0.5154 | Trifarotene | DB12808 | |
0.5140 | (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid | DB08121 |